Vincristine News and Research

RSS
Vincristine is the active ingredient in a drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Vincristine is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.
Radiation therapy plus PCV chemotherapy improves survival of low-grade glioma patients

Radiation therapy plus PCV chemotherapy improves survival of low-grade glioma patients

Abnormal breakage of chromosomes in white blood cells triggers aggressive form of ALL

Abnormal breakage of chromosomes in white blood cells triggers aggressive form of ALL

Positive bosutinib response for elderly blast phase CML patient

Positive bosutinib response for elderly blast phase CML patient

CASI Pharmaceuticals receives $10.3 million in strategic financing

CASI Pharmaceuticals receives $10.3 million in strategic financing

Scientists uncover novel strategy to block cancer's spread, restore tumor vulnerability to chemotherapy

Scientists uncover novel strategy to block cancer's spread, restore tumor vulnerability to chemotherapy

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Marqibo now available to leukemia patients through myTomorrows' Internet-based platform

Marqibo now available to leukemia patients through myTomorrows' Internet-based platform

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

Phase 1 BelCHOP study shows belinostat and CHOP chemo regimen as first-line treatment for PTCL

CASI reports net loss of $1.6 million for third quarter 2015

CASI reports net loss of $1.6 million for third quarter 2015

Researchers pinpoint mechanisms that cause chemoresistance in ovarian cancer patients

Researchers pinpoint mechanisms that cause chemoresistance in ovarian cancer patients

CASI reports financial results for second quarter 2015

CASI reports financial results for second quarter 2015

Rare BCR-ABL fusions highlighted in CML

Rare BCR-ABL fusions highlighted in CML

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Doxorubicin omission feasible for select Wilms’ tumour patients

Doxorubicin omission feasible for select Wilms’ tumour patients

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015

CASI Pharmaceuticals reports net loss of $1.8 million for first quarter 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

May issue of Red Journal focuses on role of radiation therapy in current lymphoma treatment

May issue of Red Journal focuses on role of radiation therapy in current lymphoma treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.